Target and Its Patented Drug(s)

Content Navigation (  All   None )                                      
Target General Information
Patent(s) and the Corresponding Patented Drug(s)
References
Target General Information  Top
Target ID T31406 Target Info
Target Name Hematopoietic cell kinase (HCK)
Synonyms p61Hck; p59Hck; p59-HCK/p60-HCK; Tyrosine-protein kinase HCK; Hemopoietic cell kinase
Target Type Patented-recorded Target
Gene Name HCK
Biochemical Class Kinase
UniProt ID
HCK_HUMAN
Patent(s) and the Corresponding Patented Drug(s)  Top
United States Patent and Trademark Office (USPTO)
Patent ID US9765037
Title Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases
Abstract Compositions and methods for the treatment of toxoplasmosis, caused by the infectious eukaryotic parasite Toxoplasma gondii (T. gondii) and for the treatment of cryptosporidiosis, caused by the infectious eukaryotic parasites Cryptosporidium parvum (C. parvum) and Cryptosporidium hominus (C. hominus) are described. In particular, the present disclosure is directed to compositions and methods for inhibiting either T. gondii calcium dependent protein kinases (TgCDPKs) or C. parvum and C. hominus calcium dependent protein kinases (CpCDPKs) using pyrazolopyrimidine and/or imidazo[1,5-a]pyrazine inhibitors, of the formula, wherein the variables X, Y, Z, L, R1, and R3 are defined herein.
Applicant(s) University of Washington Through its Center for Commercialization
Representative Drug(s) D07FAF Drug Info IC50 > 10000nM Click to Show More [1]
2 D04XHJ Drug Info IC50 > 10000nM [1]
3 D0Y9PK Drug Info IC50 > 10000nM [1]
Patent ID US9765037
Title Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases
Abstract Compositions and methods for the treatment of toxoplasmosis, caused by the infectious eukaryotic parasite Toxoplasma gondii (T. gondii) and for the treatment of cryptosporidiosis, caused by the infectious eukaryotic parasites Cryptosporidium parvum (C. parvum) and Cryptosporidium hominus (C. hominus) are described. In particular, the present disclosure is directed to compositions and methods for inhibiting either T. gondii calcium dependent protein kinases (TgCDPKs) or C. parvum and C. hominus calcium dependent protein kinases (CpCDPKs) using pyrazolopyrimidine and/or imidazo[1,5-a]pyrazine inhibitors, of the formula, wherein the variables X, Y, Z, L, R1, and R3 are defined herein.
Applicant(s) University of Washington Through its Center for Commercialization
Representative Drug(s) D07FAF Drug Info IC50 > 10000nM Click to Show More [1]
2 D04XHJ Drug Info IC50 > 10000nM [1]
3 D0Y9PK Drug Info IC50 > 10000nM [1]
Patent ID US9765037
Title Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases
Abstract Compositions and methods for the treatment of toxoplasmosis, caused by the infectious eukaryotic parasite Toxoplasma gondii (T. gondii) and for the treatment of cryptosporidiosis, caused by the infectious eukaryotic parasites Cryptosporidium parvum (C. parvum) and Cryptosporidium hominus (C. hominus) are described. In particular, the present disclosure is directed to compositions and methods for inhibiting either T. gondii calcium dependent protein kinases (TgCDPKs) or C. parvum and C. hominus calcium dependent protein kinases (CpCDPKs) using pyrazolopyrimidine and/or imidazo[1,5-a]pyrazine inhibitors, of the formula, wherein the variables X, Y, Z, L, R1, and R3 are defined herein.
Applicant(s) University of Washington Through its Center for Commercialization
Representative Drug(s) D07FAF Drug Info IC50 > 10000nM Click to Show More [1]
2 D04XHJ Drug Info IC50 > 10000nM [1]
3 D0Y9PK Drug Info IC50 > 10000nM [1]
Patent ID US9724347
Title 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl) ureas as P38 MAP knase inhibitors
Abstract There are provided compounds of formula (I) which are inhibitors of the family of p38 mitogen-activated protein kinase enzymes, and to their use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as asthma and COPD.
Applicant(s) Respivert, Ltd.
Representative Drug(s) D0Y4TK Drug Info N.A. [2]
Patent ID US9108950
Title 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl) ureas as p38 MAP kinase inhibitors
Abstract There is provided a compound of formula (I) which is an inhibitor of the family of p38 mitogen-activated protein kinase enzymes, and to its use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as asthma and COPD.
Applicant(s) Respivert, Ltd.
Representative Drug(s) D0H0SM Drug Info N.A. [3]
Patent ID US9062066
Title Anti-inflammatory compound having inhibitory activity against multiple tyrosine kinases and pharmaceutical composition containing same
Abstract The present invention is for the anti-inflammatory compounds that have an inhibitory activity against protein tyrosine kinases and their pharmaceutical composition(s) containing the compound as the active ingredient. Since the compounds of the present invention can inhibit multiple protein kinases associated with inflammatory diseases and immune disorders, they are useful for their prevention or treatment.
Applicant(s) KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
Representative Drug(s) D0D5PL Drug Info IC50 = 4.4 nM [4]
Patent ID US8933228
Title Respiratory formulations and compounds for use therein
Abstract The present invention relates to respiratory formulations comprising a compound of formula (I): and use of said compounds and compositions in treatment, for example in the treatment of an inflammatory disease or a respiratory disorder, in particular an inflammatory mediated and/or virally mediated respiratory disorder such as asthma and COPD or the treatment or prevention of viral infection, for example infection by influenza virus, rhinovirus or RSV. The invention also extends to certain novel compounds of formula (I).
Applicant(s) Respivert, Ltd.
Representative Drug(s) D0B7VP Drug Info IC50 = 2 nM Click to Show More [5]
2 D07PDQ Drug Info IC50 = 47 nM [5]
3 D05CDF Drug Info IC50 > 1894nM [5]
Patent ID US8933228
Title Respiratory formulations and compounds for use therein
Abstract The present invention relates to respiratory formulations comprising a compound of formula (I): and use of said compounds and compositions in treatment, for example in the treatment of an inflammatory disease or a respiratory disorder, in particular an inflammatory mediated and/or virally mediated respiratory disorder such as asthma and COPD or the treatment or prevention of viral infection, for example infection by influenza virus, rhinovirus or RSV. The invention also extends to certain novel compounds of formula (I).
Applicant(s) Respivert, Ltd.
Representative Drug(s) D0B7VP Drug Info IC50 = 2 nM Click to Show More [5]
2 D07PDQ Drug Info IC50 = 47 nM [5]
3 D05CDF Drug Info IC50 > 1894nM [5]
Patent ID US8933228
Title Respiratory formulations and compounds for use therein
Abstract The present invention relates to respiratory formulations comprising a compound of formula (I): and use of said compounds and compositions in treatment, for example in the treatment of an inflammatory disease or a respiratory disorder, in particular an inflammatory mediated and/or virally mediated respiratory disorder such as asthma and COPD or the treatment or prevention of viral infection, for example infection by influenza virus, rhinovirus or RSV. The invention also extends to certain novel compounds of formula (I).
Applicant(s) Respivert, Ltd.
Representative Drug(s) D0B7VP Drug Info IC50 = 2 nM Click to Show More [5]
2 D07PDQ Drug Info IC50 = 47 nM [5]
3 D05CDF Drug Info IC50 > 1894nM [5]
References  Top
REF 1 Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases. US9765037.
REF 2 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl) ureas as P38 MAP knase inhibitors. US9724347.
REF 3 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl) ureas as p38 MAP kinase inhibitors. US9108950.
REF 4 Anti-inflammatory compound having inhibitory activity against multiple tyrosine kinases and pharmaceutical composition containing same. US9062066.
REF 5 Respiratory formulations and compounds for use therein. US8933228.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.